ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial
Research output: Contribution to journal › Article › peer-review
Colleges, School and Institutes
To investigate the tolerability, pharmacokinetics, and antitumor activity of the oral, selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 in patients with solid malignant tumors.
|Number of pages||11|
|Journal||Journal of Clinical Oncology|
|Publication status||Published - 2002|